List of investigational attention deficit hyperactivity disorder drugs
List of Investigational Attention Deficit Hyperactivity Disorder Drugs
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. It affects both children and adults and can significantly impact daily functioning and quality of life. Over the years, various medications have been developed to manage ADHD symptoms, including stimulants like methylphenidate and amphetamine, as well as non-stimulant medications such as atomoxetine and guanfacine. However, not all patients respond well to these treatments, leading to ongoing research into new, investigational drugs. This article provides an overview of investigational drugs for ADHD, highlighting their mechanisms of action, current status in clinical trials, and potential benefits.
Investigational Stimulants[edit | edit source]
Stimulants are the most commonly prescribed medications for ADHD, working by increasing levels of certain neurotransmitters in the brain to improve attention and focus. Investigational stimulants aim to offer similar benefits but with fewer side effects or longer-lasting effects.
Example Stimulant Drug[edit | edit source]
- Compound Name: (Leave blank)
- Mechanism of Action: (Leave blank)
- Clinical Trial Phase: (Leave blank)
- Potential Benefits: (Leave blank)
Investigational Non-Stimulants[edit | edit source]
Non-stimulant medications are an important alternative for patients who do not respond well to stimulants or who experience adverse effects. These drugs often target different neurotransmitter systems in the brain.
Example Non-Stimulant Drug[edit | edit source]
- Compound Name: (Leave blank)
- Mechanism of Action: (Leave blank)
- Clinical Trial Phase: (Leave blank)
- Potential Benefits: (Leave blank)
Novel Mechanisms of Action[edit | edit source]
Research into ADHD treatments is also exploring drugs with novel mechanisms of action. These may include modulation of neurotransmitter systems not traditionally targeted by current ADHD medications.
Example Drug with Novel Mechanism[edit | edit source]
- Compound Name: (Leave blank)
- Mechanism of Action: (Leave blank)
- Clinical Trial Phase: (Leave blank)
- Potential Benefits: (Leave blank)
Challenges and Future Directions[edit | edit source]
Developing new drugs for ADHD presents several challenges, including understanding the complex neurobiology of ADHD, ensuring safety and efficacy in pediatric populations, and addressing the diverse needs of ADHD patients. Future research directions may focus on personalized medicine approaches, long-acting formulations, and treatments with minimal side effects.
See Also[edit | edit source]
This list is incomplete; you can help WikiMD by expanding it.
The field of ADHD treatment is evolving, with ongoing research into new pharmacological options. This list represents a snapshot of investigational drugs currently under study and is not exhaustive. As research progresses, new compounds will emerge, and existing ones may advance through clinical trials or be discontinued based on their safety and efficacy profiles.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD